About The Study: The results of this study suggest a benefit associated with the availability of effective therapies for melanoma in the past decade and further suggest that the use of new pharmacological therapies is associated with a decrease in the melanoma mortality rate in the U.S. population. These data are very encouraging and support the continued development of such therapies. Additionally, the accessibility of these treatments and the associated health care costs needs to be addressed.
Authors: Navkirat Kahlon, M.D., M.P.H., of the University of Toledo College of Medicine and Life Sciences in Toledo, Ohio, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.45269)
